“Global Radiopharmaceutical Market” Report of Market Research Future explores Scope of the Study as Research Objective, Assumptions and Limitations in-depth. The report gives Market Dynamics by Drivers, Restraints, Opportunities, Challenges, Macroeconomic Indicators and Technology Trends & Assessment.
Radiopharmaceutical Market – Overview
As the healthcare industry is moving towards the personalized approaches, the role of radiopharmaceutical is also increasing. The radiopharmaceutical is acting as an all-rounder radiopharmaceutical from diagnosis to treatment for various chronic diseases such as cancers and other neurological disorders, which has provided an impetus to the market.
Demand for radiopharmaceuticals is growing due to raising awareness about availability of radiation and radioisotopes in medicine, particularly for diagnosis and therapy for various chronic conditions. In developed countries about one person in 50 uses diagnostic nuclear medicine every year, and the demand for therapy with radioisotopes is about one-tenth of this.
Radiopharmaceuticals use radiation to provide diagnostic information about the functioning of a person’s specific organs while radiotherapy can be used to treat some medical conditions, especially cancer, used to weaken or destroy particular targeted cells.
Request Sample copy at https://www.marketresearchfuture.com/sample_request/1650
Radiopharmaceutical Market – Segmentation:
The global radiopharmaceutical market is segmented by type, type of test, application, route of administration, and end user.
By type, it is segmented into diagnostic type radiopharmaceuticals and therapeutic type radiopharmaceuticals. Diagnostic type radiopharmaceutical is further sub-segmented into SPECT radiopharmaceutical and PET radiopharmaceutical. Therapeutic type radiopharmaceutical is further sub-segmented into beta emitters, alpha emitters, brachytherapy. SPECT radiopharmaceutical is further sub-segmented into Technetium-99m, Thallium-201, Iodine-123, and others. PET radiopharmaceutical is further sub-segmented into F-18, Rubidium-82, and others. While, beta emitters are sub-segmented into Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177, and others. And, brachytherapy is sub-segmented into Iodine-125, Iridium-192, Cesium-131, and others.
By type of test, it is segmented into myocardial perfusion scan, lung scan, bone scan, white blood cell scan, gallium scan, renal nuclear medicine scan, parathyroid scans, hepatobiliary scans, cerebral perfusion scan and others. Whereas, a bone scan is further sub-segmented into Technetium-99m 1st, fluoride-18 2nd, and others. Myocardial Perfusion Scan, Type is sub-segmented into Technetium-99m, Thallium-201, Rubidium-82, and others. The lung scan by type is segmented into Xenon-133, Krypton-81m, and others. And, White blood cell Scan is sub-segmented into Indium-111 and others.
By application, it is segmented into oncology, cardiology, neurology, urology, and others. Oncology segment is further segmented into following applications; prostate cancer, bone cancer, breast cancer and others. Cardiology segment is further segmented into following applications; coronary artery disease, cardiomyopathy and others. Neurology segment is further segmented into following applications such as traumatic brain injury, stroke, Alzheimer’s disease and others. Urology is sub-segmented into acute pyelonephritis, congenital renal anomalies, and others.
By Route of Administration, it is segmented into oral, intravenous and others.
By End User, it is segmented into hospitals, diagnostic centers, research institutes and others.
Players Covered:
Some of the key players in this market are Jubilant Life Sciences Ltd., Siemens AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Cardinal Health Inc., Medtronic, General Electric Company (GE Healthcare), Lantheus Medical Imaging, Inc., Advanced Accelerator Applications S.A., Mallinckrodt Pharmaceuticals, Nordion, Inc., Canadian Nuclear Laboratories (CNL), Bracco Diagnostic Inc., IBA Dosimetry GmbH, Avid Radiopharmaceuticals and few others.
Radiopharmaceutical Market – Regional Analysis:
The global radiopharmaceutical market is segmented into four major regions including Americas, Europe, Asia Pacific and the Middle East & Africa. Among these, Americas and Europe will continue to present lucrative growth opportunities for market players during the forecast period. Currently, these two regions collectively account for the largest share of the market and the trend is likely to continue over the next couple of years. Higher healthcare spending and existence a robust healthcare system system in these regions is reflecting favorably on the market. In Asia Pacific, increased focus on improving the quality of healthcare services is auguring well for market players operating in the region. During the review period, the market in the region is expected to capture a strong CAGR.
Browse Complete 271 Pages Premium Research Report Enabled with 481 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650
Major TOC of Radiopharmaceutical Market Research Report – Forecast to 2023:
1 Report Prologue
2 Executive Summary
3 Market Introduction
4 Research Methodology
5 Market Dynamics
6 Market Factor Analysis
7 Global Radiopharmaceutical Market, by Type
8 Global Radiopharmaceuticals Market, by Type of Test
9 Global Radiopharmaceutical Market, by Application
10 Global Radiopharmaceutical Market, by Route of Administration
11 Global Radiopharmaceutical Market, by End-User
12 Global Radiopharmaceutical Market, by Region
13 Competitive Landscape
14 Company Profile
15 Appendix
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312